share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

Recursion Pharmaceuticals | 4：持股變動聲明-高管 Gibson Christopher
美股SEC公告 ·  09/07 05:00
牛牛AI助理已提取核心訊息
Recursion Pharmaceuticals CEO Christopher Gibson completed a sale of 40,000 shares of the company's Class A Common Stock on September 4 and 5, 2024. The transactions were executed at prices ranging from $6.04 to $6.14 per share, resulting in a total market value of $243,600. Following the sales, Gibson directly holds 762,656 shares of Recursion Pharmaceuticals.
Recursion Pharmaceuticals CEO Christopher Gibson completed a sale of 40,000 shares of the company's Class A Common Stock on September 4 and 5, 2024. The transactions were executed at prices ranging from $6.04 to $6.14 per share, resulting in a total market value of $243,600. Following the sales, Gibson directly holds 762,656 shares of Recursion Pharmaceuticals.
Recursion Pharmaceuticals首席執行官Christopher Gibson於2024年9月4日和5日完成了對公司A類普通股的40,000股股份的銷售。這些交易的執行價格介於6.04美元至6.14美元每股，總市值爲243,600美元。銷售完成後，Gibson直接持有Recursion Pharmaceuticals的762,656股股份。
Recursion Pharmaceuticals首席執行官Christopher Gibson於2024年9月4日和5日完成了對公司A類普通股的40,000股股份的銷售。這些交易的執行價格介於6.04美元至6.14美元每股，總市值爲243,600美元。銷售完成後，Gibson直接持有Recursion Pharmaceuticals的762,656股股份。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。